Form 4: Neurocrine Legal Officer Exercises Options, Sells Shares

Neurocrine Biosciences' Chief Legal Officer, Darin Lippoldt, executed a pre-arranged 10b5-1 plan, exercising stock options and selling 4,376 common shares.

Summary

• Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc. (NBIX), reported a transaction on December 8, 2025.
• Lippoldt exercised 4,376 non-qualified stock options at an exercise price of $43.24 per share.
• Concurrently, 4,376 shares of common stock were sold at a weighted average price of $159.647 per share, with prices ranging from $159.50 to $159.76.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2025.
• Following these transactions, Lippoldt beneficially owns 43,405 shares of Neurocrine Biosciences common stock.
• The exercised options were granted on February 6, 2017, vested monthly over four years, and were due to expire on February 6, 2027.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (option exercise and sale under a 10b5-1 plan) which is generally neutral. It reflects personal financial planning rather than a direct positive or negative signal about the company's immediate prospects.

Positives

• The exercise of stock options indicates that the Chief Legal Officer saw value in converting options to shares.
• The sale was executed at a significantly higher price ($159.647) than the exercise price ($43.24), demonstrating a substantial gain for the insider.

Negatives

• The Chief Legal Officer sold 4,376 shares of common stock, which represents a reduction in direct beneficial ownership.

Risks

• While executed under a 10b5-1 plan, insider selling, even if pre-scheduled, can sometimes be perceived negatively by investors as it reduces management's direct equity stake.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely an insider transaction report.

Management Comments

• The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025.
• Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
• The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Industry Context

This Form 4 filing details a routine insider transaction, specifically the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. Such transactions are common among executives for personal financial planning and diversification, and typically do not reflect a change in the company's operational outlook or broader industry trends unless they are unusually large or frequent.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Legal Officer, even under a 10b5-1 plan, slightly reduces insider ownership, which some investors might view with minor concern, though it's a common practice for diversification.

Next Steps

• NA

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Darin Lippoldt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Chief Legal Officer, Equity Sales